RGRichard Peter Gale

Richard Peter Gale

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Richard Peter Gale has a total of 96 co-authors. Here are the top co-authors by number of shared publications:

  • Archana Airody

    York Teaching Hospitals NHS Foundation Trust, Wigginton Road, York, Yo31 8HE, UK

    2 shared publications
  • Divya Venugopal

    Academic Unit of Ophthalmology, York Teaching Hospitals NHS Foundation Trust, York, North Yorkshire, UK

    2 shared publications
  • Gavin Walters

    Harrogate and District NHS Foundation Trust, Harrogate, UK

    2 shared publications
  • A Maisey

    The Action on DMO group, UK

    1 shared publication
  • Aaron Y Lee

    Department of Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, UK

    1 shared publication
  • Academic Unit Of Ophthalmology Consultant Medical Ophthalmologist And Honorary Senior Clinical Lecturer

    1 shared publication

Latest Publications

  • Open Access

    The management of neovascular age‐related macular degeneration: A systematic literature review of patient‐reported outcomes, patient mental health and caregiver burden

    by Richard P. Gale, Robert P. Finger, Bora Eldem, Tariq Aslam, Jane Barratt, Vincent Daien, Laurent Kodjikian, Anat Loewenstein, Mali Okada, Tien Yin Wong, et al.

    Purpose: The aim of this systematic literature review was to describe patient‐reported outcomes, mental health and caregiver burden in patients with neovascular age‐related macular degeneration (nAMD) treated with anti‐vascular endothelial growth factor (VEGF) agents in routine clinical practice.Methods: Electronic searches were conducted in Embase and MEDLINE according to pre‐defined criteria.Results: Of 856 records identified, 63 met inclusion criteria. Depression or depressive symptoms were reported in up to 42% of patients with nAMD. Of 25/63 (40%) studies evaluating quality of life (QoL) and using various tools, eight studies reported composite National Eye Institute Visual Functioning Questionnaire scores following anti‐VEGF treatment. Of these, seven reported a statistically significant improvement at the earliest time point measured (Month 3–12) and approximately 50% reported sustained QoL benefits at 12 months. In studies comparing the attributed or different regimens, the most important factor from the patient's perspective was the likelihood that a particular regimen would maintain vision. There was a preference towards treat and extend, which was associated with a perceived reduction in patient and caregiver burden, compared to fixed dosing.Conclusions: A coordinated holistic approach to patient care is key to optimizing patient well‐being as well as visual outcomes. Further research regarding the patient‐reported impact of nAMD management outside the trial setting (particularly international longitudinal studies) is warranted. Standardization of QoL studies would assist in establishing whether sustained QoL improvement, rather than prevention of QoL decline, should be a realistic expectation of treatment of nAMD in the longer term.


  • Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injections

    by Richard Gale, Claire Gill, Maria Pikoula, Aaron Y Lee, Rachel L W Hanson, Spiros Denaxas, Catherine Egan, Adnan Tufail, Paul Taylor, UK EMR Database Users Group

    Background/Aims To assess the effectiveness, burden and safety of two categories of treatment for central retinal vein occlusion (CRVO): intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) and dexamethasone (Ozurdex). Methods A retrospective analysis of Medisoft electronic medical record (EMR) data from 27 National Health Service sites in the UK identified 4626 treatment-naive patients with a single mode of treatment for macular oedema secondary to CRVO. Statistics describing the overall CRVO patient cohort and individual patient subpopulations stratified by treatment type were generated. Mean age at baseline, gender, ethnicity, social deprivation and visual acuity (VA) follow-up was reported. Absolute and change in VA using ETDRS are used to describe treatment effectiveness, the number of injections and visits used to describe treatment burden and endophthalmitis rates as a marker of treatment safety. Results Mean VA was 47.9 and 45.3 EDTRS letters in the anti-VEGF and Ozurdex groups, respectively. This changed to 57.9/53.7 at 12 months, 58.3/46.9 at 18 months and 59.4/51.0 at 36 months. Mean number of injections were 5.6/1.6 at 12 months, 6.0/1.7 at 18 months and 7.0/1.8 at 36 months. Endophthalmitis rates were 0.003% (n=4) for the anti-VEGF group and 0.09% (n=1) for the Ozurdex group. Conclusions VA improvements were greater and more sustained with anti-VEGF treatment. Lower starting acuity resulted in bigger gains in both groups, while higher starting acuity resulted in higher VA at 36 months. Although treatment burden was greater with anti-VEGF, Ozurdex was associated with higher rates of endophthalmitis.


  • Open Access

    Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study

    by Richard P Gale, Ian Pearce, Nicole Eter, Faruque Ghanchi, Frank G Holz, Steffen Schmitz-Valckenberg, Konstantinos Balaskas, Ben J L Burton, Susan M Downes, Haralabos Eleftheriadis, et al.

    Background/Aims Prospective data on switching anti-vascular endothelial growth factors in patients with neovascular age-related macular degeneration (nAMD) who have previously shown no/partial response are limited. This prospective study assessed the effect of switching from aflibercept to ranibizumab on anatomical and functional outcomes in patients with persistent/recurrent disease activity. Methods SAFARI (NCT02161575) was a 6-month, prospective, single-arm study conducted in the UK and Germany. Patients, meeting strict eligibility criteria for one of two subgroups (primary treatment failure or suboptimal treatment response), received 3 monthly intravitreal ranibizumab injections (0.5 mg). Thereafter, ranibizumab was administered pro re nata at monthly visits. The primary endpoint was change from baseline (CfB) to day 90 in central subfield retinal thickness (CSRT). Best-corrected visual acuity (BCVA) and retinal morphology parameters were assessed. Results One hundred patients were enrolled (primary treatment failure, 1; suboptimal treatment response, 99). In the overall population, there was a significant CfB in median CSRT of −30.75 µm (95% CI −59.50,–20.50; pConclusion Switching from aflibercept to ranibizumab led to a significant improvement in CSRT, with ~60% experiencing stabilised/improved BCVA. Therefore, patients with nAMD who have shown a suboptimal response to aflibercept may benefit from switching to ranibizumab.


  • Open Access

    Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service

    by Richard P. Gale, Sajjad Mahmood, Helen Devonport, Praveen J. Patel, Adam H. Ross, Gavin Walters, Louise Downey, Samer El-Sherbiny, Mary Freeman, Simon Berry, et al.

    This publication and the expert roundtable meeting on which the article is based were sponsored by Bayer plc. Prescribing information for Eylea® (aflibercept solution for injection) can be found at the end of the article.


  • Open Access

    Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease

    by R Gale, P H Scanlon, M Evans, F Ghanchi, Y Yang, G Silvestri, M Freeman, A Maisey, J Napier

    This paper identifies best practice recommendations for managing diabetes and sight-threatening diabetic eye disease. The authors provide an update for ophthalmologists and allied healthcare professionals on key aspects of diabetes management, supported by a review of the pertinent literature, and recommend practice principles for optimal patient management in treating visual impairment due to diabetic eye disease. In people with diabetes, early optimal glycaemic control reduces the long-term risk of both microvascular and macrovascular complications. The authors propose more can and should be done to maximise metabolic control, promote appropriate behavioural modifications and encourage timely treatment intensification when indicated to ameliorate diabetes-related complications. All people with diabetes should be screened for sight-threatening diabetic retinopathy promptly and regularly. It is shown that attitudes towards treatment adherence in diabetic macular oedema appear to mirror patients’ views and health behaviours towards the management of their own diabetes. Awareness of diabetic macular oedema remains low among people with diabetes, who need access to education early in their disease about how to manage their diabetes to delay progression and possibly avoid eye-related complications. Ophthalmologists and allied healthcare professionals play a vital role in multidisciplinary diabetes management and establishment of dedicated diabetic macular oedema clinics is proposed. A broader understanding of the role of the diabetes specialist nurse may strengthen the case for comprehensive integrated care in ophthalmic practice. The recommendations are based on round table presentations and discussions held in London, UK, September 2016.


  • The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis

    by Gregory Heath, Archana Airody, Richard Peter Gale

    Recent times have seen an increase in the number of options to treat multiple sclerosis. Ocular manifestations of multiple sclerosis are well known to treating physicians; however, the medications used to treat multiple sclerosis can also have ocular side effects. This review article focuses on the ocular manifestations of corticosteroids and disease-modifying agents such as interferon, fingolomod, natalizumab, alemtuzumab and mitoxantron used to treat the disease. The ocular manifestations of multiple sclerosis treatments can be varied depending on the drug used, and include retinopathy, chronic central serous chorioretinopathy, macular oedema, Graves’ ophthalmopathy and cortical blindness. These effects may be specific to the drug or secondary to their immunosuppressive effect. The association of macular oedema with fingolomod is clear and merits ocular screening for toxicity. The immunosuppressive nature of the treatments makes patients prone to acquired infections. Hence, if a patient with multiple sclerosis presents with vision loss, infectious and drug-induced aetiology should be considered alongside relapses of multiple sclerosis itself as a cause.


  • Open Access

    Characteristics and Predictors of Early and Delayed Responders to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Retrospective Analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials

    by Richard Gale, Jean-Francois Korobelnik, Yit Yang, Tien Y. Wong

    Purpose: This retrospective review examined visual acuity (VA) in subjects with neovascular age-related macular degeneration and identified early and delayed response to ranibizumab. Procedures: MARINA, ANCHOR, HARBOR, and CATT published data were examined for response with monthly versus individualized dosing and predictors of early versus delayed response. Results: Data were available for 1,631 subjects; 18-29% were early gainers and 15-16% were delayed gainers. Of the early gainers, 72-83% maintained their best-corrected VA gain at month 12 with monthly or individualized dosing. Delayed gainers in HARBOR almost reached the same level of response as early gainers by 12 months who were able to maintain their response. The main predictor of response was baseline VA. Conclusion: There are two distinct types of ranibizumab response; some responded by month 3, while others took up to 12 months. In delayed responders, this may have implications for switching or not switching therapies.


  • Open Access

    The Importance of Ocular, Systemic and Psychosocial Factors in the Management of the Diabetic Macular Oedema Patient with Antivascular Endothelial Growth Factor Therapy

    by Richard Gale, York York Teaching Hospital Nhs Foundation Trust, Angela Carneiro, Julie de Zaeytijd, Paul Dodson, Sascha Fauser, João Figueira, Michael Larsen, Nicolas Leveziel, Michael Kapusta, et al.

    Acomprehensive list of patient features that influence the management of patients with diabetic macular oedema (DMO) is discussed. These features are grouped into three overarching themes: ocular, systemic and psychosocial. Consensus statements about the relative importance of these features, supported by the literature, were formed by a panel of retinal experts. The major drivers influencing the management of DMO with anti-vascular endothelial growth factor (anti-VEGF) therapy are undoubtedly ocular specific, in particular visual acuity and optical coherence tomography (OCT) central retinal thickness. Systemic factors, such as control of glycated haemoglobin (HbA 1c ), blood pressure and serum lipid estimations, have limited direct influence on DMO management although they remain important considerations to communicate to the primary diabetic physician. A greater understanding is required on how many other factors, in particular psychosocial factors, influence the care of the DMO patient.


  • Endogenous Mycotic Endophthalmitis

    by Richard P. Gale, Miles Stanford

  • Endogenous Bacterial Endophthalmitis

    by Richard P. Gale, Bruno Zuberbuhler, Miles R. Stanford